2021 CSCO | Latest Results of Two Phase II Clinical Studies of Akeso’s PD-1/VEGF Bispecific Antibody (AK112) for Treatment of Lung Cancer and Ovarian Cancer
2021-09-23

(HONG KONG, 23 Sept 2021) Akeso, Inc. (the Company, 9926.HK) announces that latest results of a phase II clinical study of the world’s first PD-1/VEGF bispecific antibody (AK112) in combination with chemotherapy for treatment of non-small-cell lung cancer (NSCLC) and a phase Ib/II clinical study of PD-1/VEGF bi-specific antibody (AK112) in combination with Olaparib for treatment of platinum-sensitive recurrent BRCA1/2 wild-type ovarian cancer, will be published at the 24th National Clinical Oncology Meeting and the 2021 Annual Meeting of Chinese Society of Clinical Oncology (CSCO) in the form of oral presentation and abstract, respectively.

 

Information of the two studies are as follows:

 

01

A multi-center, open-label phase II clinical study (AK112-201) of anti-PD-1/VEGF bi-specific antibody AK112 in combination with chemotherapy for treatment of advanced NSCLC

Form of reporting: Oral presentation

Speaker: Prof. Zhang Li, Affiliated Tumor Hospital of Sun Yat-sen University

Study results: As of the data cutoff date, 37 treatment-naïve NSCLC subjects have received treatment of AK112 in combination with chemotherapy, showing good safety profile and favorable anti-tumor activity.

 

02

A phase Ib/II clinical study of PD-1/VEGF bi-specific antibody AK112 in combination with Olaparib for treatment of platinum-sensitive recurrent BRCA1/2 wild-type ovarian cancer patients

Form of reporting: Abstract

First author: Prof. Wu Lingying, Cancer Hospital Chinese Academy of Medical Sciences

Study results: AK112 as monotherapy for treatment of platinum-sensitive recurrent ovarian cancer and AK112 in combination with PARP inhibitor Olaparib for treatment of platinum-sensitive recurrent BRCA1/2 wild-type ovarian cancer patients have both shown favorable anti-tumor efficacy. The study is ongoing and data will be updated.

 

About AK112 (PD-1/VEGF Bi-Specific Antibody)

AK112 is a first-in-class and the first to enter clinical trial PD-1/VEGF bi-specific antibody independently developed by the Company. Engineered with our unique TETRABODY technology, AK112 blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors. PD-1 antibody in combination with VEGF blocking agents have shown robust efficacy in various tumor types (including renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma). In the view of the co-expression of VEGF and PD-1 in the tumor microenvironment, AK112, as a single agent to block these two targets, may block these two pathways more effectively and enhance the anti-tumor activity, as compared to combination therapy.

 

 

About Akeso, Inc.

Akeso, Inc. is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable   to patients worldwide. Since the Company’s establishment, the Company has established an end-to-end comprehensive drug development platform (ACE Platform) and system, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC production process development, and GMP compliant scale production. The Company has also successfully developed a bi-specific antibody drug development technology (Tetrabody technology). The Company currently has a pipeline of over 20 innovative drugs for the treatment of major diseases like tumors, autoimmune diseases, inflammation and metabolism diseases, 13 of which have entered clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). In Aug 2021, the Company’s first in-house innovatively researched and developed differentiated PD-1 monoclonal antibody Penpulimab monoclonal antibody injection (安尼可®) was approved to the market. The Company’s vision is to become a global leading biopharmaceutical company through research and development of high efficacy and breakthrough new drugs that are first-in-class and best-in-class therapies.